PanCystPro
Pre-clinical- Indications
- Pancreatic cancer
Company intelligence / Profile preview
Amplified Sciences has developed and clinically validated a proprietary optical reporter diagnostic platform enabling highly sensitive detection of disease biomarkers from small sample volumes. Their lead product, PanCystPro, detects protease activity in pancreatic cyst fluid to help stratify malignancy risk in patients with pancreatic cystic lesions—a key challenge in early detection of pancreatic cancer. The company’s CLIA lab received regulatory approval in November 2023 and began commercial processing as an LDT in early/mid–2024. Published data show superior accuracy versus standard-of-care diagnostics. Additional assays are under development targeting other challenging diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Amplified Sciences.